Biotech and healthcare stocks outperformed the broader market in the week ended Oct. 23, with XBI up 3.6%, IBB up 2.9% and XLV up 1.5%, while SPY fell 0.4%. Oruka Therapeutics (ORKA) is set to report 16-week results from its Phase 2b Everlast-B trial of Orka-001 in plaque psoriasis on Monday, and Summit Therapeutics (SMMT) reported Harmoni-GI1 data showing ivonescimab plus chemotherapy cut the risk of death by 25% versus durvalumab plus chemotherapy in advanced biliary tract cancer. The week’s calendar also includes earnings from Novartis, Eli Lilly, Merck, GSK and others, plus FDA target dates, including Inovio’s INO-3107 on Friday. ESMO Congress continues through Tuesday in Madrid, with updates from Incyte and Iovance.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
pharmaceuticalsearningsFDAhealthcare
Open a keyword to see other news on the same topic.
Related tickers and likely impact
SPY
• NeutralSPDR S&P 500 ETF
Relevance: low
| Market | US stocks |
|---|---|
| Sector | ETF |
| Close on 10/23/2026 | 759.85 |
| Change that session | -0.54% |
Impact is scored by AI from the headline and may be wrong. It is not investment advice.
Related news
- Why This Hair Restoration Biotech's Shares Are Soaring
Veradermics (MANE) shares are up 268% since the company’s February 4 IPO, driven by positive phase 3 data for VDPHL01, an extended-release oral minoxidil. In the trial, 78.8% of patients on the daily dose and 85% on the twice-daily dose reported improved hair coverage, versus 35.3% on placebo. If approved, it would be the first oral minoxidil approved by the FDA and an alternative to finasteride, though the company has not given a timeline for its New Drug Application. The company estimates the pattern hair loss market will be worth more than $30 billion by 2028 and reported $820 million in cash as of Q2, enough to fund operations into 2030. The company has no revenue, and the average analyst price target is $170.
- Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026
Mineralys Therapeutics presented new data on lorundrostat at ASN Kidney Week 2026 in Denver, Colorado, from the Phase 3 Launch-HTN trial. Systolic blood pressure reductions were similar in participants with and without CKD across Stages 1-3. At week 12, lorundrostat reduced placebo-adjusted systolic blood pressure by 9.6 mmHg in participants with CKD and 12.2 mmHg in those without. In participants with CKD and baseline albuminuria, the urine albumin-to-creatinine ratio fell 52.2% versus placebo. The drug is under FDA review for hypertension in combination with other antihypertensives, with a PDUFA target date of December 22, 2026.
- New bipartisan bill aims to speed up clinical trials for rare disease treatments
Bipartisan Reps. Jake Auchincloss (D) and Morgan Griffith (R) introduced the "Faster Clinical Trials Act" to speed up studies of rare disease treatments, one week after the FDA unveiled a new initiative for these drugs. The bill would create a network of reusable clinical trial sites and a "Center for Clinical Trial Innovation" at the FDA, with up to $75 million in annual funding over five years. Its goal is to cut trial costs and enrollment time by at least 30%, and to let patients receive experimental drugs at their regular doctor's office, with progress tracked through Zoom, electronic health records or wearables. Griffith said this would also help patients who live hours away from medical centers.
- Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy
Exelixis shares have risen 49% this year, but the FDA has extended the review of zanzalintinib, its investigational colorectal cancer drug, with a decision now expected by March 3, 2027, instead of December 3, 2026. The article argues the outlook remains attractive, citing three factors. First, Cabometyx, its main revenue driver, posted second-quarter revenue up 10.6% year over year to $628.7 million, and patent protection should keep generics out of the U.S. until at least 2030. Second, some analysts estimate zanzalintinib could generate $4.5 billion in U.S. sales by 2033, compared with $2.3 billion in revenue last year. Third, Exelixis has several other early-stage candidates and research collaborations in its pipeline.
- Viatris Receives U . S . FDA Approval for RYZUMVI® for the Treatment of Presbyopia
The U.S. FDA has approved Viatris' RYZUMVI (phentolamine ophthalmic solution 0.75%) for treating presbyopia, the age-related loss of near focusing ability, in adults. The drug was already approved in the U.S. for pharmacologically induced mydriasis, and the new approval expands its use. Viatris holds exclusive U.S. commercialization rights under a licensing deal with Opus Genetics and is exploring a U.S. partner to commercialize RYZUMVI for presbyopia. The most common ocular side effects reported for presbyopia were conjunctival hyperemia (21%) and instillation site irritation (16%), and the drug is not recommended for patients with active ocular inflammation.
- 2 Under-the-Radar Stocks to Buy and Hold
The author sees Axsome Therapeutics (AXSM) and Exelixis (EXEL) as attractive biotech stocks despite less investor attention than leading AI companies. Axsome's Auvelity sales rose 51% year over year to $180.3 million in the second quarter, about 82.6% of the company's $218.4 million revenue, and the drug recently gained approval for Alzheimer's disease agitation and is in a Phase 3 study for smoking cessation. Sunosi sales grew 20% to $35.8 million, and an AXS-12 application could be approved by May 2027. Exelixis posted $628.7 million in second-quarter revenue, up almost 11%, with its main drug Cabometyx protected from U.S. generics until at least 2030. The FDA extended the review for zanzalintinib to March 3, 2027, but the author believes approval remains likely.
Related markets
Latest news
- Chip Stocks to Buy After Their Worst Day Since June
The PHLX Semiconductor Index fell 6.7% on Oct. 22, its worst day since June 23, after Lam Research reported record revenue of $8.22 billion but warned that clean-room space and parts shortages would limit chipmakers' ability to meet demand into 2027. Micron expects memory supply to stay tight in 2027 and 2028, yet its stock is down 29% from its June 25 record close. AMD and Marvell are each about 22% below their Oct. 6 closes. The author says all three are worth considering after the drop, with Micron the first to look at because its price seems to reflect a downturn its own outlook does not show. AMD and Marvell carry higher earnings multiples and need their plans to hold up, and a slowdown in AI spending could still hit all three hard.
- Will gold prices keep falling this week?
On the morning of Oct. 26, domestic gold prices kept falling with global prices, as SJC gold bars were quoted at 138.7–141.7 million VND per luong (buy–sell), down 300,000 VND from the weekend. World gold was quoted at $3,986 an ounce, down $7 from the previous morning. In Kitco News' weekly survey, 7 of 17 experts expected prices to fall this week, 4 expected a rise, and 6 saw a sideways move or no clear trend. The article says prices may keep falling in the short term, but buying could emerge once gold drops below $4,000 an ounce.
- Banks pledge to lead and unlock momentum for Southeast Vietnam
A conference titled “Banking sector supporting capital mobilization for Southeast region growth, 2026-2030,” organized by the State Bank of Vietnam with the HCMC People's Committee, saw 18 cooperation agreements aimed at adding resources for key projects in the region. HDBank and Vikki Digital Bank pledged 124,500 billion VND for four projects in HCMC and Dong Nai, excluding their co-financing of Metro lines 4–5, while VietinBank, Agribank, MB and Vietcombank also committed funds to transport, industrial and social housing projects. The SBV said 35 key projects nationwide need about 1.7 quadrillion VND in loans, including 15 in the Southeast needing about 757,000 billion VND, and it has mechanisms to exclude these loans from or add to banks' credit growth quotas. HDBank urged faster land clearance, legal completion and data sharing to shorten appraisal times, and it raised a 721 million USD social loan in 2026.
- Proposal to fine violators up to 3 billion VND, cut off electricity, water and internet
On the morning of Oct. 26, Minister of Public Security Lương Tam Quang submitted to the National Assembly the government's draft amended Law on Handling Administrative Violations, with 6 chapters and 128 articles, raising maximum fines to 1.5 billion VND for individuals and 3 billion VND for organizations. The draft also extends limitation periods to 1–3 years depending on the field, from 1–2 years under the current law, and adds enforcement measures such as suspending exit, sealing premises, cutting electricity and water supply, and suspending internet and telecom services. The minister stressed stricter conditions for these measures to protect rights and avoid affecting uninvolved individuals and organizations. The National Assembly's review committee agreed the law needs comprehensive revision but asked for further review of the extended periods by field and more fundamental remedies than higher fines, and said cutting off electricity, water and internet is aimed at halting violations rather than enforcing penalty decisions, so these provisions need adjustment.
- Gold steadies near 3-mth low as elevated oil prices weigh; Fed meet eyed
Gold held steady in Asian trade on Monday after falling more than 4% last week, at $3,995.42 an ounce. The metal slipped below $4,000 on Friday for the first time since mid-July, mainly due to an oil surge amid elevated Middle East conflict, with Brent up 6.2% last week to its highest weekly close since mid-2022. Higher energy costs could prolong inflation pressures and limit central banks' room to ease policy. Investors widely expect the Fed to keep rates unchanged at its Oct. 27–28 meeting, while CME FedWatch data showed about a 78% probability of a December rate hike. The 10-year US Treasury yield near 5% keeps pressure on non-yielding gold, and the PCE inflation report due Oct. 29 will be the next test for the inflation outlook.
- Hong Kong names Nasdaq-listed Solana Company a strategic enterprise
Hong Kong has named Nasdaq-listed Solana Company (HSDT) a strategic enterprise under the Office for Attracting Strategic Enterprises (OASES) program, making it the only blockchain infrastructure firm onboarded in 2026. The company said the designation gives it a single point of contact across government agencies and regulators, faster pathways to recruit overseas talent, and introductions to local institutional partners. Solana Company runs staking and validator infrastructure, advises financial institutions on blockchain adoption, and holds Solana (SOL) as part of its digital asset treasury strategy. It plans to set up validator operations in Hong Kong under Pacific Backbone, an initiative to build a low-latency blockchain network across Asia-Pacific.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.